Manel Merabet
Chief Development Officer SKYMAB Biotherapeutics
Seminars
Tuesday 19th August 2025
Workshop A
9:00 am
Choosing the ideal conjugation site is critical for maximizing ADC stability and ensuring efficient release at the target site. This workshop will explore how
strategic conjugation site selection can enhance linker durability and improve ADC performance.
This workshop will cover:
- Understanding the influence of the chemical environment on conjugation site selection to improve hydrophobicity control
- Leveraging structural modeling and analytical tools to explore viable conjugation sites
- Balancing linker exposure to prevent premature cleavage while ensuring efficient release at the target site
- Exploring the impact of different conjugation chemistries (e.g., beta-glucuronidase, thiomaleimide) on site accessibility and stability
- Using hydrophobicity profiling and hydrophobic interaction chromatography to assess linker exposure
Thursday 21st August 2025
Advancing Site-Specific ADC Conjugation: Skymab’s Next-Generation Platform & First Preclinical Insights
1:00 pm
- Innovations in site-specific ADC conjugation – overcoming the limitations of traditional maleimide chemistry
- Skymab’s novel platform – enhancing stability, DAR control, and therapeutic index through optimized linker strategies
- Preclinical results and future directions – first insights into Skymab’s lead ADC candidate and its potential clinical impact
